Diasome Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Diasome Pharmaceuticals, Inc. - overview
Established
2004
Location
Cleveland, OH, US
Primary Industry
Biotechnology
About
Diasome Pharmaceuticals, Inc. is a US-based biotechnology firm specializing in innovative therapeutic solutions for metabolic disorders, focusing on advanced delivery systems to enhance patient care. Founded in 2004 and headquartered in Cleveland, US, Diasome Pharmaceuticals, Inc. develops therapeutic technologies for metabolic health.
The company was established by Robert Geho and has engaged in multiple funding rounds, including a Series C round in June 2023, raising USD 9. 000 mn, bringing the total amount raised to USD 9. 000 mn and a current valuation of USD 119. 156 mn.
Diasome Pharmaceuticals, Inc. provides innovative therapeutic solutions targeting metabolic disorders, particularly through its HDV technology. This technology aims to restore hepatocyte metabolism, addressing deficiencies related to conditions such as Type 1 Diabetes and Dyslipidemia. The HDV system supports both injectable and oral administration methods to meet diverse patient needs, leveraging drug payload advancements to optimize therapeutic outcomes for healthcare providers and patients with metabolic diseases.
The revenue model of Diasome Pharmaceuticals, Inc. is built on partnerships and direct-to-consumer sales for its HDV technology. Collaborations with healthcare providers facilitate product distribution to patients managing metabolic conditions, with revenue stemming from structured agreements that may involve bulk purchasing by medical facilities or direct supply to pharmacies, ensuring competitive pricing aligned with market demands. With the recent Series C funding round completed in June 2023, in which Diasome Pharmaceuticals, Inc.
raised USD 9. 000 mn, the company plans to focus on expanding its product offerings and entering new geographic markets. In February 2024, they intend to launch upcoming products utilizing the latest technology advancements. The funding will be directed towards broadening their reach in regions significantly impacted by metabolic disorders, enhancing distribution channels, and supporting ongoing research in metabolic treatment solutions.
Current Investors
Medicxi, JDRF T1D Fund, Black Beret Life Sciences
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.diasome.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Diasome Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.